To review the previously published studies on pharmacokinetics and pharmacodynamics of chiral drugs used in the treatment of asthma.
DATA SOURCES:
Primary and review articles were identified with a MEDLINE search (1980–May 2001) and through secondary sources.
STUDY SELECTION AND DATA EXTRACTION:
All English-language studies and reviews obtained from the MEDLINE search pertaining to stereoselective pharmacokinetics and pharmacodynamics of chiral anti-asthma drugs were assessed.
DATA SYNTHESIS:
Several anti-asthma drugs (e.g., β2-adrenergic agonists, leukotriene modifiers) are chiral and marketed as racemates, which consist of equal proportions of 2 enantiomers. Significant stereoselectivity has also been reported in pharmacodynamics and pharmacokinetics of the β2-agonists. The enantiomers of β2-agonists in the R configuration are primarily responsible for the bronchodilating effects of the racemate. The plasma concentrations of the enantiomers of anti-asthma drugs may differ as a reflection of stereoselectivity in clearance, volume of distribution, and route of administration.
CONCLUSIONS:
Stereoselectivity in the pharmacokinetics of anti-asthma drugs may complicate the relationship between dose and/or plasma concentration of racemic drug versus effect relationship. An appreciation of the stereoselective pharmacokinetics and pharmacodynamics of chiral anti-asthma drugs may optimize the use of these agents in asthmatic patients.
GrammerLC. Basic pharmacotherapy of asthma. Chest1992; 101 (suppl 6):405S–6S.
7.
DrazenJM. New directions in asthma drug therapy. Hosp Pract1998; 33: 25–38.
8.
BarnesPJ. The drug therapy of asthma: Direction for the 21st century. Agents Actions Suppl1988; 23: 293–313.
9.
MorganDJ. Clinical pharmacokinetics of β-agonists. Clin Pharmacokinet1990; 18: 270–94.
10.
Garcia-MarcosLSchusterA. New perspectives for asthma treatment: Anti-leukotriene drugs. Pediatr Allergy Immunol1999; 10: 77–88.
11.
BalaniSKXuXPrathaVKossMAAminRDDufresneC. Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile. Drug Metab Dispos1997; 25: 1282–7.
12.
JamaliFMehvarRPasuttoFM. Enantioselective aspects of drug action and disposition: Therapeutic pitfalls. J Pharm Sci1989; 78: 695–715.
13.
HuttAJTanSC. Drug chirality and its clinical significance. Drugs1996; 52 (suppl 5):1–12.
14.
BrocksDRJamaliF. Stereochemical aspects of pharmacotherapy. Pharmacotherapy1995; 15: 551–64.
15.
MitraSUgurMUgurOGoodmanHMMcCulloughJRYamaguchiH. (S)-Albuterol increases intracellular free calcium by muscarinic receptor activation and a phospholipase C-dependent mechanism in airway smooth muscle. Mol Pharmacol1998; 53: 347–54.
16.
RyrfeldtAEdsbackerSPauweisR. Kinetics of the epimeric glucucorticoid budesonide. Clin Pharmacol Ther1984; 35: 525–30.
17.
HanselTTSchwarzFVilligerBNaefRRichardsonBPMorleyJ. Anomalous bronchospasm following inhalation of (+) isoprenaline by asthmatic. Agents Actions Suppl1993; 43: 281–8.
18.
BoultonDWFawcettJP. Enantioselective disposition of salbutamol in man following oral and intravenous administration. Br J Clin Pharmacol1996; 41: 35–40.
19.
WardJKDowJDallowNEynottPMilleriSVentrescaGP. Enantiomeric disposition of inhaled, intravenous and oral racemic-salbutamol in man — No evidence of enantioselective lung metabolism. Br J Clin Pharmacol2000; 49: 15–22.
20.
SchmekelBRydbergINorlanderBSjöswardKNAhlnerJAnderssonRG. Stereoselective pharmacokinetics of S-salbutamol after administration of the racemate in healthy volunteers. Eur Respir J1999; 13: 1230–5.
21.
Gumbhir-ShahKKellermanDJDeGrawSKochPJuskoWJ. Pharmacokinetics and pharmacodynamics of cumulative single doses of inhaled salbutamol enantiomers in asthmatic subjects. Pulm Pharmacol Ther1999; 12: 353–62.
22.
BoultonDWFawcettJP. Pharmacokinetics and pharmacodynamics of single oral doses of albuterol and its enantiomers in humans. Clin Pharmacol Ther1997; 62: 138–44.
23.
BorgstromLLiuCXWalhagenA. Pharmacokinetics of the enantiomers of terbutaline after repeated oral dosing with racemic terbutaline. Chirality1989; 1: 174–7.
24.
BorgstromLNybergLJonssonSLinbergCPaulsonJ. Pharmacokinetic evaluation of terbutaline in man given as separate enantiomers and as the racemate. Br J Clin Pharmacol1989; 27: 49–56.
25.
WongSLAwniWMCavanaughJHel-ShourbagyTLockeCSDubeLM. The pharmacokinetics of single oral doses of zileuton 200 to 800 mg, its enantiomers, and its metabolites, in normal healthy volunteers. Clin Pharmacokinet1995; 29 (suppl 2):9–21.
26.
MehvarRJamaliF. Bioequivalence of chiral drugs. Stereospecific versus non-stereospecific methods Clin Pharmacokinet1997; 32: 122–41.
27.
KimKYHParkYH. Enantioselective inclusion between terbutaline enantiomers and hydroxypropyl-β-cyclodextrin. Int J Pharm1998; 175: 247–53.
28.
WalleUKPesolaGRWalleT. Stereoselective sulphate conjugation of salbutamol in humans: Comparison of hepatic, intestinal and platelet activity. Br J Clin Pharmacol1993; 35: 413–8.
29.
BoultonDWFawcettJP. Determination of salbutamol enantiomers in human plasma and urine by chiral high-performance liquid chromatography. J Chromatogr B1995; 672: 103–9.
30.
BorgstromLKennedyBMNilssonBAngelinB. Relative absorption of the two enantiomers of terbutaline after duodenal administration. Eur J Clin Pharmacol1990; 38: 621–3.
31.
HartmanAPWilsonAAWilsonHMAbergGFalanyCNWalleT. Enantioselective sulfation of β2-receptor agonists by the human intestine and the recombinant M-form phenolsulfotransferase. Chirality1998; 10: 800–3.
32.
BoultonDWFawcettJPFiddesTM. Transplacental distribution of salbutamol enantiomers at Caesarian section. Br J Clin Pharmacol1997; 44: 587–90.
33.
MachinistJMKukulkaMJBoppBA. In vitro plasma protein binding of zileuton and its N-dehydroxylated metabolite. Clin Pharmacokinet1995; 29 (suppl 2):34–41.
34.
BoultonDWFawcettJP. Enantioselective disposition of albuterol in humans. Clin Rev Allergy Immunol1996; 14: 115–38.
35.
WilsonAAWangJKochPWalleT. Stereoselective sulphate conjugation of fenoterol by human phenolsulphotransferases. Xenobiotica1997; 27: 1147–54.
36.
EatonEAWalleUKWilsonHMAbergGWalleT. Stereoselective sulphate conjugation of salbutamol by human lung and bronchial epithelial cells. Br J Clin Pharmacol1996; 41: 201–6.
37.
WalleTWalleUKThornburgKRScheyKL. Stereoselective sulfation of albuterol in humans: Biosynthesis of sulfate conjugate by HEP G2 cells. Drug Metab Dispos1993; 21: 76–80.
38.
ZhangMFawcettJPKennedyJMShawJP. Stereoselective glucuronidation of formoterol by human liver microsomes. Br J Clin Pharmacol2000; 49: 152–7.
39.
KamimuraHSasakiHHiguchiSShiobaraY. Quantitative determination of the β2-adrenoreceptor stimulant formoterol in urine by gas chromatography mass spectrometry. J Chromatogr1982; 229: 337–45.
40.
ArvidssonPLarssonSLofdahlCG. Objective and subjective bronchodilation over 12 hours after inhaled formoterol: Individual responses. J Asthma1993; 30: 459–65.
41.
SweenyDJNellansHN. Stereoselective glucuronidation of zileuton isomers by human hepatic microsomes. Drug Metab Dispos1995; 23: 149–53.
42.
SweenyDJNellansHN. Enantiomeric activation of zileuton glucuronidation in dog microsomes. J Biol Chem1992; 267: 13171–4.
43.
KurosawaNOwadaEKatoABandoKItoKKurosawaS. Serum concentration and cardiovascular effects of salbutamol after oral and rectal administration in healthy volunteers. J Clin Pharm Ther1993; 18: 103–8.
44.
IOC Medical Commission list of prohibited substances and methods. Lausanne, Switzerland: IOC Medical Commission, 1999.
45.
BergesRSeguraJVenturaRFitchKDMortonARFarreM. Discrimination of prohibited oral use of salbutamol from authorized inhaled asthma treatment. Clin Chem2000; 46: 1365–75.
46.
BrittainRTFarmerJBMarshallRJ. Some observations on the -adrenoceptor agonist properties of the isomers of salbutamol. Br J Pharmacol1973; 48: 144–7.
47.
HartleyDMiddlemissD. Absolute configuration of the optical isomers of salbutamol. J Med Chem1971; 14: 995–6.
48.
HawkinsCJKleaseGT. Relative potency of (–)- and (plus–)-salbutamol on guinea pig tracheal tissue. J Med Chem1973; 16: 856–7.
49.
JeppssonABJohanssonUWaldeckB. Steric aspects of agonism and antagonism at beta-adrenoceptors: Experiments with the enantiomers of terbutaline and pindolol. Acta Pharmacol Toxicol1984; 54: 285–91.
50.
KiyomotoAIwasawaYHarigayaS. Studies on tetrahydroisoquinolines (THI). VI. Effects of trimetoquinol on tracheal and some other smooth muscles. Arzneimittelforschung1970; 20: 46–52.
MartinPPuechAJBrochetDSoubriePSimonP. Comparison of clenbuterol enantiomers using four psychopharmacological tests sensitive to beta-agonists. Eur J Pharmacol1985; 117: 127–9.
53.
WaldeckBWidmarkE. Steric aspects of agonism and antagonism at beta-adrenoceptors: Experiments with the enantiomers of clenbuterol. Acta Pharmacol Toxicol1985; 56: 221–7.
54.
LindbergSKhanRRunerT. The effects of formoterol, a long-acting β2-adrenoceptor agonist, on mucociliary activity. Eur J Pharmcol1995; 285: 275–80.
55.
WaldeckB. Biological significance of the enantiomeric purity of drugs. Chirality1993; 5: 350–5.
56.
DobbinsDEBuehnMJDabneyJM. Stereospecificity of the anti-inflammatory action of terbutaline. Microcirc Endothelium Lymphatics1990; 6: 3–20.
57.
DobbinsDEBuehnMJDabneyJM. Bradykinin-mediated edema formation is blocked by levorotatory but not dextrorotatory terbutaline. Microcirc Endothelium Lymphatics1988; 4: 377–97.
58.
PennRBFrielleTMcCulloughJRAbergGBenovicJL. Comparison of R, S, and R, S-albuterol interaction with human β1- and β2-adrenergic receptors. Clin Rev Allergy Immunol1996; 14: 37–45.
59.
HandleyDAWalleTFangKOHettRGaoY. Preclinical and metabolic profiles of (RR)-eformoterol (abstract). Ann Allergy Asthma Immunol1997; 78: 94.
60.
RamsayCMCowanJFlanneryEMcLachlanCTaylorDR. Bronchoprotective and bronchodilator effects of single doses of (S)-salbutamol, (R)-salbutamol, and racemic salbutamol in patients with bronchial asthma. Eur J Clin Pharmacol1999; 55: 353–9.
61.
CockroftDWSwystunVA. Effect of single doses of S-salbutamol, R-salbutamol, racemic salbutamol, and placebo on the airway response to methacholine. Thorax1997; 52: 845–8.
62.
DahlbergEThalenABrattsandRGustafssonJKJohanssonURoempkeK. Correlation between chemical structure, receptor binding, and biological activity of some novel, highly active, 16α-, 17α-acetal substituted glucocorticoids. Mol Pharmacol1984; 25: 70–8.
63.
Perrin-FayolleMBlumPSMorleyJGrosclaudeMChambeMT. Differential responses of asthmatic airways to enantiomers of albuterol. Clin Rev Allergy Immunol1996; 14: 139–47.
64.
WaldeckB. Enantiomers of bronchodilating β2-adrenoceptor agonists: Is there a cause for concern?J Allergy Clin Immunol1999;103 (5 part 1):742–8.
65.
HandleyDAMcCulloughJRCrowtherSDMorleyJ. Sympathomimetic enantiomers and asthma. Chirality1998; 10: 262–72.
66.
HandleyD. The asthma-like pharmacology and toxicology of (S)-isomers of β agonists. J Allergy Clin Immunol1999; 104 (2 part 2):S69–76.
67.
SpitzerWOSuissaSErnstPHorwitzRIHabbickBCockroftD. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med1992; 326: 501–6.
68.
LeffARHerrnreiterANaclerioRMBaroodyFMHandleyDAMuñozNM. Effect of enantiomeric forms of albuterol on stimulated secretion of granular protein from human eosinophils. Pulm Pharmacol Ther1997; 10: 97–104.
69.
NelsonHSBenschGPleskowWWDiSantostefanoMSDeGrawSReasnerDS. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J Allergy Clin Immunol1998; 102 (6 part 1):943–52.
70.
HandleyDATinkelmanDNoonanMRollinsTESniderMECaronJ. Dose—response evaluation of levalbuterol versus racemic albuterol in patients with asthma. J Asthma2000; 37: 319–27.
71.
HandleyDA. Single-isomer beta-agonists. Pharmacotherapy2001; 21 (3 part 2):21S–7S.
72.
HandleyDAAndersonAJKoesterJSniderME. New millennium bronchodilators for asthma: Single-isomer beta agonists. Curr Opin Pulm Med2000; 6: 43–9.
